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Abstract Peptidoglycan (PGN) is a ubiquitous bacterial membrane product that, despite its
well known pro-inflammatory properties, has also been invoked in immuno-tolerance of the
gastrointestinal tract. PGN-induced mucosal IL-10 secretion and downregulation of Toll like re-
ceptors are potential mechanisms of action in the gut but there are few data on tolerogenic
adaptive immune responses and PGN. Here, using blood-derived mononuclear cells, we showed
that PGN induced marked cell surface expression of PD-L1 but not PD-L2 or CD80/CD86, and
specifically in the CD14+ monocytic fraction. This was reproduced at the gene level with
rapid induction (b4 h) and, unlike for LPS stimulation, was still sustained at 24 h. Using trans-
fected and native muramyl dipeptide (MDP), which is a cleavage product of PGN and a specific
NOD2 agonist, in assays with wild type cells or those from patients with Crohn's disease carrying
the Leu1007 frameshift mutation of NOD2, we showed that (i) both NOD2 dependent and inde-
pendent signalling (appearing TLR2 mediated) occurred for PGN upregulation of PD-L1 (ii) upre-
gulation is lost in response to MDP in patients with the homozygous mutation and (iii) PD-L1
upregulation was unaffected in patients with heterozygous mutations as previously reported
for cytokine responses to MDP. The uptake of PGN and its cleavage products by the intestinal
mucosa is well recognised and further work should consider PD-L1 upregulation as one potential
mechanism of the commensal flora-driven intestinal immuno-tolerance. Indeed, recent work23 437 515.
rc-hnr.cam.ac.uk (J.J. Powell).
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163Peptidoglycan induces PD-L1 upregulation in primary monocytic cellshas shown that loss of PD-L1 signalling in the gut breaks CD8+ T cell tolerance to self antigen and
leads to severe autoimmune enteritis.
© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Pathogen associated molecular patterns (PAMPs) such as pep-
tidoglycans (PGN) and lipopolysaccharides (LPS) have long
been known for their pro-inflammatory properties, typically
inducing cytokines from mononuclear cells such as IL-1β,
TNF-α, IL-6 and IL-8. Signalling occurs via cell surface toll-
like receptors (TLRs) and also via intracellular Nod-like recep-
tors such as NOD1 and NOD2 which are the receptors for dis-
tinct peptidoglycan moieties namely meso-diaminopimelic
acid (meso-DAP) [1,2] and N-acetyl-muramyldipeptide
(MDP), respectively [3,4]. However, more recently, there
has been increasing evidence that, at least in the gastrointes-
tinal tract, the presence of PAMPs such as LPS and PGN is re-
quired for downregulation of inflammation and normal gut
health [5,6]. Moreover, polymorphisms of NOD2 that lead
to loss of function with respect to MDP pro-inflammatory
signalling, are associated with an increased risk of the
inflammatory bowel disease, Crohn's disease. Several fac-
tors could explain these apparent paradoxical observations.
First it is now clear that, in addition to pro-inflammatory
signalling, PAMPs may also stimulate cellular secretion of
the regulatory cytokine IL-10 [7,8]. Secondly, cells of the
gut are hyporesponsive with respect to pro-inflammatory
signalling [9] and, in the absence of additional signalling
from invasive bacteria, may be conditioned to respond tol-
erantly to PAMPs. Indeed it has been proposed that constitu-
tive MDP exposure provides the requisite signal that, through
IRF4 upregulation, leads to TLR downregulation on intestinal
cells [10].
Less is understood about tolerance through acquired im-
mune signalling in the gut although, recently, Reynoso et al.
showed that loss of PD-L1 (B7-H1) signalling in the intestine
breaks CD8+ T cell tolerance to self-antigen and leads to se-
vere autoimmune enteritis [11]. The Gram-negative bacterial
cell-wall component, LPS, is known to stimulate PD-L1 expres-
sion in primary mononuclear cells [12] but this has not yet
been demonstrated for the ubiquitous bacterial component
(gram positive and gram negative), PGN, although there is lim-
ited evidence for such an effect via TLR2 in B cell cancers [13].
Here we demonstrate, in primary monocytic cells, that PGN
specifically stimulates PD-L1 expression and, using Crohn's
disease derived mutants, that this occurs through both
NOD2 dependent and NOD2 independent mechanisms. Thus
APC expression of PD-L1 in the gut may provide another mech-
anism through which luminal PAMPs, such as PGN, promote
immuno-tolerance and downregulate mucosal inflammation
and autoimmune enteritis.2. Materials and methods
The study was approved by the research ethics committees
of Cambridge (reference 03/296 and 05/Q0108/355).2.1. Cell preparation and isolationTo investigate PD-L1 cell surface expression and the time
course of PD-L1 gene expression following PAMP exposure,
20 ml heparinised venous blood was obtained from healthy
volunteers, following informed consent. In some instances,
buffy coats were also purchased from the national blood
service. Peripheral blood mononuclear cells (PBMC) were
then isolated by density gradient centrifugation and, when
required, PBMC were further enriched for either monocytes
or T cells by negative isolation (Dynal, Invitrogen Ltd., UK).2.1.1. Stimulation of cells for measurement of surface
antigen expression by flow cytometry
Cell suspensions at 1.106 cells/ml were incubated at 37 °C
in 5% CO2/95% air for 3 h in 1 ml of tissue culture medium
(TCM) (RPMI 1640 (Sigma) supplemented with 10% fetal calf
serum (PAA laboratories), 2 mM L-glutamine (Sigma) and
penicillin/streptomycin (Sigma; 100 U/ml and 100 μg/ml re-
spectively)) with either 10 ng/ml LPS Escherichia Coli
(Sigma-Aldrich, UK), 5 μg/ml PGN Staphylococcus Aureus
(Sigma-Aldrich) or saline (Sigma-Aldrich) before washing and
re-suspending in fresh TCM for the remaining period of incuba-
tion (21 h). To obtain a dose response curve, 1.106 cells/ml
were stimulated with increasing doses (ranging from 0.1 to
10 μg/ml) of PGN from S.Aureus and incubated for 24 hours.
In some experiments, 4 mM calcium chloride was included
with the PAMPs described above to induce the formation of
calcium phosphate [14] and act as a transfection agent. For
the examination of cell surface markers, enriched monocytic
cells were stained after stimulation with recommended vol-
umes of the combined antibodies: (i) FITC-PD-L1 (BD
557266), PE-PD-L2 (BD 558066) and PerCP Cy5.5-CD14 (BD
550787) (ii) FITC-CD80 (BD 557266), PE-CD14 (BD 555398) and
PE Cy5-CD86 (BD 555659), or (iii) PE PD-L1 (Biolegend 317410)
and PerCP Cy5.5 CD14 (BD 550787). Cells were stained for
20 min on ice, in the dark, before washing and fixing with 1%
para-formaldehyde and protected from light thereafter. Amin-
imum of 50,000 events per sample were immediately acquired
using an EPICS XL-MCL flow cytometer (Beckman Coulter) and
EXPO32 ADC software for acquisition and analysis or CYAN
ADP flow cytometer and SUMMIT software for acquisition and
analysis (Beckman Coulter).
2.1.2. Stimulation of cells for PD-L1 gene expression
PBMC were incubated at 1.106 cells/ml for 4, 8 and 24 h
in 1 ml of TCM with either 10 ng/ml LPS from E. Coli
(Sigma-Aldrich, UK), 10 ng/ml ultra pure LPS from E. coli
(Invivogen), 10 μg/ml PGN from S. Aureus (Sigma-
Aldrich), 10 μg/ml purified PGN from S. aureus (Invivogen,
UK), 10 μg/ml soluble purified PGN from E. coli (Invivogen,
UK), 10 μg/ml synthetic MDP (Sigma-Aldrich), 10 μg/ml syn-
thetic MDP (Alexis, UK) or equivalent volume of saline
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at 37 °C in 5% CO2/95% air, cells were centrifuged at
1500 rpm for 10 min and the pellet of cells prepared for RNA
extraction.
2.2. Influence of genotype on cellular responses
to PAMPs
To investigate whether NOD2 genotype influences PD-L1 gene
expression and ensuing cytokine production following PAMP
exposure, 20 ml heparinised venous blood was obtained from
NOD2-genotype-stratified patients with Crohn's disease during
their attendance at gastroenterology out-patient clinics and
also from healthy volunteer laboratory staff. A summary of
basic demographic data at baseline is given in Table 1.
Monocyte-enriched suspensions at 1.106 cells/ml were in-
cubated for 8 h in 1 ml of TCM containing either 10 μg/ml
MDP (Sigma-Aldrich), 10 μg/ml PGN (Sigma-Aldrich) or equiva-
lent volume of saline (Sigma-Aldrich) as a negative control. To
further facilitate MDP entry into the cytosol, cell suspensions
were also incubated with MDP and 4 mM calcium chloride
which, in the presence of the high phosphate-containing
TCM, induces the formation of calcium phosphate [14], and
acts as a transfection agent. Following incubation at 37 °C in
5% CO2/95% air, cells were centrifuged at 1500 rpm for
10 min. Supernatants were collected and analysed by ELISA
for TNF-α and IL-8 according to manufacturers' instructions
(R&D systems). Cell pellets were prepared for RNA extraction.
2.3. Real time RT-PCR
Unless otherwise stated, reagents/equipment were sup-
plied by Applied Biosystems, UK. Following experimental
treatment, cultured cells were lysed in Total RNA Lysis Solu-
tion and stored at −70 °C prior to RNA isolation. Total RNA
was extracted using the ABI PRISM 6100 Nucleic Acid Pre-
spStation according to the manufacturer's instructions.
This included a DNAse treatment using AbsoluteRNA Wash
Solution. Extracted RNA concentration and quality were de-
termined using a NanoDrop ND-1000 Spectrophotometer
(Labtech International Ltd., UK). Synthesis of cDNA was per-
formed using TaqMan Reverse Transcription Reagents withTable 1
Summary of basic demographic data for patients and
healthy volunteers, at baseline.
Subject Gender Genotype
Crohn's disease patient 1 Female L1007fs/L1007fs
Crohn's disease patient 2 Female L1007fs/L1007fs
Crohn's disease patient 3 Male R702W/L1007fs
Crohn's disease patient 4 Male R702W/L1007fs
Healthy control 1 Male WT
Healthy control 2 Male WT
Healthy control 3 Female WT
Healthy control 4 Male WT
Healthy control 5 Female WT
Healthy control 6 Male WTrandom hexamers on a GeneAmp PCR System 9700 Thermal
Cycler. Relative mRNA expressions for TNF-α, IL-8 and 18S
housekeeping control or PD-L1 were determined on an Applied
Biosystems 7000 Sequence Detection System using SYBR Green
JumpStart Taq ReadyMix (Sigma-Aldrich, UK) or TaqMan Gene
Expression Assays/Gene Expression Master Mix on an Applied
Biosystems 7500 Fast Real-Time PCR System under standard
reaction conditions. The following primer pair sequences (for-
ward and reverse, respectively) were used with SYBR Green:
TNF-α (5′-CCTGCCCCAATCCCTTTATT-3′, 5′-CCCTAAGCCCC-
CAATTCTCT-3′ [15], IL8 (5′-ATGACTTCCAAGCTGGCCGTG-3′,
5′-TCTCAGCCCTCTTCAAAAACTTCTC-3′ [16] and 18S (5′-
CGGCTACCACATCCAAGGAA-3′, 5′-GGCTGCTGGCACCAGACTT-
3′ [17]). Relative mRNA expressions for PD-L1 and 18S house-
keeping control were determined using TaqMan Gene
Expression Assays as above (primer sequences not available
from Applied Biosystems). Results were calculated using
the ΔΔCt method and for statistical analysis expressed as
log2 gene fold-inductions relative to the untreated control.
2.4. Statistics
Differences in PGN and MDP responses between healthy sub-
jects and patients with Crohn’disease were analysed by un-
paired t tests. Differences among means were considered
significant at P values b 0.05.
3. Results
Peripheral blood mononuclear cells (PBMC), enriched for
monocytic cells from healthy donors and stimulated for 3 h
with PGN from S. Aureus, increased by 5 fold (i.e. from 18%
to 90%) the number of CD14+ gated cells that showed en-
hanced PD-L1 protein cell surface expression at 24 h as mea-
sured by mean fluorescence intensity (Figs. 1A and B).
Moreover, the mean fluorescence intensity (MFI) for all
CD14+ gated cells increased in a dose responsive fashion
upon exposure to PGN from S. Aureus (Fig. 1C). Unexpectedly,
LPS did not lead to a significant increase in PD-L1 expression
(Figs. 1D and E). The PGN effect, however, was specific
for PD-L1 amongst the inducible B7 proteins as it was not
observed for PD-L2 (Fig. 1B) or CD80 (Supplemental Fig. 1)
at 24 h. Expression did not increase significantly for CD86
(Supplemental Fig. 1), although this could have been due to
slower expression kinetics of the ligand [18,19]. The PGN ef-
fect on PD-L1 was specific to the monocytic cell fraction (i.e.
CD14+) and was not observed for CD14− cells (Fig. 1F). Thus,
in further work, monocytic enrichment was not always consid-
ered necessary. Previous work with a synthetic viral PAMP,
namely Poly I:C, has shown that PD-L1 up-regulation is tran-
scriptionally driven [20]. To determine this for PGN,we under-
took real time PCR analyses of the PD-L1 gene at 4, 8 and 24 h
following stimulation of PBMC again with crude PGN of S. aure-
us. Expression peaked at 8 h (range of linear induction 12–40
fold) but was also strongly apparent (7–22 fold) at 4 h and
was retained at 24 h (Fig. 2A). To confirm that the effect
was due to PGN and not some minor contaminant we also
used purified PGN from S. aureus and showed a similar pattern
of PD-L1 upregulation, albeit slightly attenuated in magnitude
(6–24 fold) (Fig. 2B). Initial responses to LPS were observed as
expected in terms of PD-L1 upregulation, but were not
Figure 1 (A). Percentage of CD14+ cells expressing PD-L1, 24 hours after stimulation with PGN from S. Aureus (5 μg/ml) (n = 5; p =
0.001 PGN versus saline). (B). Example fluorescence density plots gated on CD14+ cells in the live monocyte gate, showing PD-L1 and
PD-L2 expression in response to PGN from S. Aureus, grey fill = saline control, no fill = PGN. (C). The effect of increasing doses of PGN
from S. Aureus on PD-L1 expression measured by mean fluorescence intensity (MFI), n = 6, baseline levels of PD-L1 staining are indi-
cated by the arrow. (D). Percentage of CD14+ cells expressing PD-L1, 24 hours after stimulation with LPS from E. Coli (10 ng/ml, n =
5). (E). Fluorescence density plots gated on CD14+ cells in the live monocyte gate, showing PD-L1 and PD-L2 expression in response to
LPS from E. Coli, grey fill = saline control, no fill = LPS. (F). PD-L1 expression on CD14+ (no fill) and CD14– (back fill) cells after PGN
stimulation.
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sponse by flow cytometric analysis (i.e. Figs. 1D and E).
To determine the importance of TLR2 versus NOD2 in the
PGN response we used purified soluble PGN which does not
engage this receptor significantly [21] but does signal through
NOD2. Weak but still significant induction of PD-L1 was
observed at 4 h (2–14 fold) and this pattern of stimulation was
closely mimicked by the synthetic NOD2 agonist muramyl di-
peptide (2–12 fold) (Fig. 2D). MDP has also been suggested to
signal through NALP1 and NALP3, at least for inflammasome ac-
tivation [22,23], so we next isolated cells from patients with
Crohn's disease carrying the rare homozygous Leu1007 frame-
shift mutation in NOD2, where an absolute failure in MDP–
NOD2 signalling is observed. To enhance gene expression signal,
we used enriched monocytes derived from PBMC and chose an
8 h time point where maximal PGN stimulation and adequate
MDP stimulation of PD-L1 mRNA were observed in healthy
cells (Figs. 2A and D). In this case MDP was unable to induce
PD-L1 gene expression (Fig. 3A; p b 0.05 versus healthysubjects) or, as expected, gene expression and secretion of
the pro-inflammatory cytokines TNF-α and IL-8 (Figs. 3A and
B; pb0.01 versus healthy subjects) implying an absolute re-
quirement for NOD2 signalling in MDP regulation of PD-L1 as
well as that already known for the pro-inflammatory cytokines.
This contrasted with the positive gene expression of PD-L1
and IL-8 as well as the secretion of TNF-α and IL-8 proteins
in healthy control cells upon MDP stimulation (Figs. 3A and
B). Finally, to confirm that the lack of MDP response in
NOD2 Leu1007fs cells was not due to poor cellular uptake
of the ligand [4], we transfected MDP using calcium phos-
phate. As anticipated, this enhanced both message and se-
cretion of IL-8 and TNF-α in healthy control cells (Figs. 3C
and 3D versus 3A and 3B), albeit not PD-L1, and showed no
effect in NOD2 Leu1007fs cells except for a small variation
for cytokine secretion around baseline levels (i.e. versus
sham transfection, Figs. 3C and D).
For PGN (S. aureus)-stimulation of the above cell types we
reasoned the opposite outcomes: namely that PD-L1 and
Figure 2 Time course of PD-L1 log2 gene expression in response to PAMPs. PD-L1 log2 gene expression following stimulation of
PBMC with (A) PGN from S. aureus (10 μg/ml) (B) purified PGN from S. aureus (10 μg/ml) (C) regular (black circle) and ultra-pure
LPS (open circle) both from E. coli (10 ng/ml) and (D) soluble PGN from E. coli (grey square; 10 μg/ml) and synthetic MDP from
two sources (open triangle from Sigma; closed triangle from Alexis; 10 μg/ml). Data are mean±SEM (n=4).
Figure 3 Influence of genotype on cellular responses to MDP. PD-L1, IL-8 and TNF-α log2 gene expression following synthetic MDP
stimulation (Sigma, 10 μg/ml) (A) without and (B) with calcium phosphate transfection in enriched monocytes isolated from healthy
controls (HC; n=6) or patients with Crohn's disease homozygous for the NOD2 Leu1007 frameshift mutation (Leu1007fs; n=2).
IL-8 and TNF-α protein secretion (pg/ml) following MDP stimulation (Sigma; 10 μg/ml) (C) without and (D) with calcium phosphate
transfection in enriched monocytes isolated from healthy controls (HC, n=6) or patients with Crohn's disease homozygous for the
NOD2 Leu1007 frameshift mutation (Leu1007fs; n=2).* pb0.05 and ** pb0.01 versus healthy controls.
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Figure 4 Influence of genotype on cellular responses to PGN. PD-L1, IL-8 and TNF-α log2 gene expression following S. aureus PGN
stimulation (10 μg/ml) (A) without and (B) with calcium phosphate transfection in enriched monocytes isolated from healthy controls
(HC; n=5) or patients with Crohn's disease homozygous for the NOD2 Leu1007 frameshift mutation (Leu1007fs; n=2). IL-8 and TNF-α
protein secretion (pg/ml) following S. aureus PGN stimulation (10 μg/ml) (C) without and (D) with calcium phosphate transfection in
enriched monocytes isolated from healthy controls (HC; n=5) or patients with Crohn's disease homozygous for the NOD2 Leu1007
frameshift mutation (Leu1007fs, n=2). * pb0.05 and ** pb0.01 versus healthy controls.
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PGN in NOD2 Leu1007fs cells due to non-NOD2 signalling,
while transfection of PGN would enhance its intracellular de-
livery such that, upon digestion to its minimal motif, namely
MDP, itwould favour the (dysfunctional) NOD2 pathway and re-
duce responsiveness to whole PGN. Indeed, PGN signalling
appeared normal in NOD2 Leu1007fs cells and, for both these
cells and healthy control cells. PD-L1 and IL-8 responses were
lower normal in NOD2 Leu1007fs cells and, in all cases, PD-L1
and IL-8 responses were lower in PGN-transfected cells versus
those receiving PGN alone (Fig. 4). Notably, upon transfection
of PGN, expression of PD-L1 and TNF-a were especially
decreased in NOD2 Leu1007fs cells (Fig. 4C, p b 0.01 and
pb0.05 versus healthy subjects, respectively) in NOD2
Leu1007fs cells (Fig. 4C). In all cases, responses to soluble
LPS were normal (Supplemental Fig. 2).
Previous work has shown that the absolute failure in
MDP–NOD2 signalling is associated only with the homozygous
NOD2 Leu1007 frameshift mutation and not single nucleotide
mutations or even compound heterozygote mutations involv-
ing NOD2 Leu1007fs. We confirmed this here for transfected
MDP induction of PD-L1 expression in enriched monocytic
cells from patients with Crohn's disease bearing NOD2 mu-
tations other than Leu1007fs (see Table 1 for patient geno-
type details). After 8 h, PD-L1 expression was upregulated
by about 4 fold (linear induction) (Supplemental Fig. 3A).
Positive responses were seen for TNF-α and IL-8 both at
the message and protein level (Supplemental Figs. 3A
and 3B).4. Discussion
The nature of the cellular response to TLR engagement de-
pends upon the level of exposure to PAMP and the site or
“compartment” of exposure (e.g. gut versus lung) [24]. Dis-
ruption of such a careful balance and abnormal TLR activa-
tion has been linked to a number of inflammatory and
autoimmune diseases, including the inflammatory bowel dis-
eases [24,25]. Since (i) under certain circumstances (e.g. in
the gut) PGN may invoke tolerogenic responses [5,6] and
(ii) PD-1 ligand interactions have been implicated in the
maintenance of tolerance and the control of autoimmunity
[11,26,27], this study aimed to investigate the expression
of PD-1 ligands following PGN/MDP stimulation of mononu-
clear cells derived from both healthy subjects and from pa-
tients with Crohn's disease carrying known NOD2 genetic
mutations. The numbers studied were inevitably low due to
the very rare occurrence of the NOD2 Leu1007fs mutation
in the population but differences were absolute and the
data, therefore, compelling.
Our findings indicate that, as with other PAMPs, PGN
stimulates the upregulation of PD-L1 in primary monocytic
cells. Both NOD2 dependent and NOD2 independent path-
ways are apparent because a distinct PGN moiety, namely
MDP, could not induce PD-L1 in cells carrying a homozygous
frameshift mutation in NOD2 whereas whole S. aureus PGN
signalled normally. The latter effect is likely to occur via
TLR2 engagement since S. aureus PGN binds this receptor
with reasonably high affinity, triggering pro-inflammatory
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from B. anthracis [30] or purified PGN from E. coli have no
such effect [21,29] and, similarly in this work, appeared
equivalent to MDP in its ability to induce PD-L1. The pathway
linking TLR or NOD engagement to PD-L1 upregulation is
unclear but the parallels with pro-inflammatory cytokine
signalling throughout this work suggest that it may involve
NF-κB activation. A second possibility concerns type I
interferons: these may be stimulated by cellular exposure to
PGN/MDP [31,32] and recent work has indicated that the
type I interferons also stimulate PD-L1 upregulation [33].
Irrespective of the mechanisms, an important question is
why microbial PAMPs, including the ubiquitous PGN struc-
ture, should at all induce a co-stimulatory molecule that is
commonly involved in immuno-tolerance in primary phago-
cytic cells? Reynoso et al. indicate that PD-1:PD-L1
interactions, or CD80:PD-L1 interactions, are vital to check
unrestrained proliferation of cytotoxic T cells during neo-
antigen presentation within a background of naïve but
antigen-specific CD8+ lymphocytes in the small intestine
[11]. In their model, inhibition of this process led to severe
autoimmune enteritis [11]. It is possible, therefore, that
this “PD-L1 safety net” is also operative during bacterial in-
fection, and driven in part by PGN, as a balance would be re-
quired to achieve clearance of the pathogen without the
development of over-zealous cytotoxic CD8+ T cells that in-
crease the risk of autoimmune responses (towards APCs or
even new targets through molecular mimicry). However, in-
creasing evidence points to a down side to such a mecha-
nism, namely that the PD-1/ligand pathway may be
exploited by pathogens as a mechanism of immune evasion.
Examples are apparent in viral, bacterial, protozoan and
parasitic worm infections [27]. In all cases it appears that
the PD-1 pathway is utilised by the pathogen to escape
host immune responses and establish persistent infection.
Parallel to the persistence of infection, PD-1 expression has
also been associated with T cell exhaustion and disease se-
verity. Correlations between viral load and PD-1 expression
on T cells have been reported in HIV infection, with lower
PD-1 expression associated with long-term non-progressors
[34,35]. Pertinent to our study, translocation of microbial
constituents from the gut into blood in HIV infection has
been reported to inhibit T cell expansion and function via
up-regulation of PD-1 and IL-10 production by monocytes,
thereby restraining HIV specific T cell responses. The sys-
temic modulation of immune responses described was in-
duced by several bacterial TLR ligands [36]. At the level of
the gut contemporary understanding is that commensal bac-
teria have an active role in both shaping and maintaining in-
testinal immunity, via TLRs and NLRs and that disruption of
such signalling risks inflammation and autoimmunity [25].
With this in mind it is even possible that purposeful acquisi-
tion occurs, of luminal PGN fragments by mucosal antigen
presenting cells, to enable PD-L1 upregulation and tolero-
genic signalling to T cells, especially following APC migration
to the mesenteric lymph nodes. Certainly, a PGN-based tol-
erogenic mechanism for the innate immune system has
been suggested by Watanabe et al. with downregulation of
TLR responses being triggered in mucosal cells following
the engagement of NOD2 by luminal PGN fragments [10].
This, or the acquired PD-L1 mechanism proposed here, re-
quire the presence of intracellular bacterial fragments inthe bowel wall and it is noteworthy that a number of reports
have demonstrated this, especially in the Peyer's patch, ter-
minal ileum and even the colon [37–39]. How such fragments
are acquired by mucosal immune cells, and whether this
leads to the induction of cell surface PD-L1 in vivo as we
have shown here in vitro, remains to be established but are
active areas of research. Finally it should be noted that PD-
1 interactions are thought to be of considerable importance
for hepatic CD4 T cell tolerance [40–41] and interestingly,
during preparation of this manuscript, Castellaneta et al.
reported that PGN induces PD-L1 expression in vivo in hepat-
ic plasmacytoid dendritic cells in a NOD2 dependent fashion
[42]. Unlike us they found no effect in in vitro cultures,
which probably reflects the different cell types investigated,
but at least adds evidence to the idea that PGN fragments
may induce the functional in vivo expression of PD-L1 in
splancnic myeloid cells. Additionally, it is noteworthy that
other TLR agonists have recently been shown to be impor-
tant for the generation of tolerogenic APC during dendritic
cell differentiation inducing a STAT-3 mediated expression
of PD-L1 [43]. Several genetic defects associated with the in-
tracellular identification and processing of bacterial compo-
nents have been identified in inflammatory bowel disorders,
and further work with gut APCs is merited. In summary, in
vitro, PGN induces PD-L1 upregulation in primary monocytic
cells which could further explain how luminal bacteria and
bacterial fragments can impact anti-inflammatory and tol-
erogenic signalling in the gut.
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